NASDAQ:INBX

Inhibrx (INBX) Stock Forecast, Price & News

$18.35

+0.14 (+0.77%)

(As of 09/29/2023 ET)

Compare

Today's Range: $17.77
▼
$18.62
50-Day Range: $15.75
▼
$24.28
52-Week Range: $15.01
▼
$34.72

Volume: 293,199 shs
Average Volume: 497,393 shs
Market Capitalization: $801.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.33

Inhibrx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 141.6% Upside
$44.33 Price Target
Short Interest: Bearish
14.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.21
Upright™ Environmental Score
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$9.90 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.08) to ($4.18) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

125th out of 972 stocks

Biological Products, Except Diagnostic Industry

17th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Inhibrx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.33, Inhibrx has a forecasted upside of 141.6% from its current price of $18.35.
Amount of Analyst Coverage
Inhibrx has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
14.40% of the float of Inhibrx has been sold short.
Short Interest Ratio / Days to Cover
Inhibrx has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Inhibrx has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inhibrx does not currently pay a dividend.
Dividend Growth
Inhibrx does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inhibrx is -1.21.

3.9

News and Social Media Coverage

News Sentiment
Inhibrx has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Inhibrx this week, compared to 1 article on an average week.
Search Interest
3 people have searched for INBX on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Inhibrx to their MarketBeat watchlist in the last 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inhibrx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,899,982.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Inhibrx are expected to decrease in the coming year, from ($4.08) to ($4.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inhibrx is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inhibrx is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inhibrx has a P/B Ratio of 13.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inhibrx (NASDAQ:INBX) Stock

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Price History

30 days | 90 days | 365 days | Advanced Chart

INBX Stock News Headlines

September 24, 2023 | americanbankingnews.com

Inhibrx (NASDAQ:INBX) Stock Price Down 2.2%

September 19, 2023 | finance.yahoo.com

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

October 1, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 29, 2023 | marketwatch.com

Inhibrx Shares Rise 15% After Private Placement Financing

August 29, 2023 | finance.yahoo.com

Inhibrx Announces $200 Million Private Placement Financing

August 23, 2023 | markets.businessinsider.com

JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know

August 23, 2023 | nasdaq.com

JMP Securities Maintains Inhibrx (INBX) Outperform Recommendation

August 23, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)

October 1, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

August 17, 2023 | msn.com

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

August 16, 2023 | markets.businessinsider.com

LifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)

August 8, 2023 | finance.yahoo.com

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

June 27, 2023 | marketwatch.com

Theft in open court: How a fight over lifesaving drugs led to accusations of brazen industrial espionage

May 30, 2023 | finance.yahoo.com

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 11, 2023 | msn.com

JMP Securities Reiterates Inhibrx (INBX) Market Outperform Recommendation

May 9, 2023 | finanznachrichten.de

Inhibrx Inc.: Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023 | finance.yahoo.com

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 8, 2023 | finance.yahoo.com

Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates

May 4, 2023 | msn.com

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

May 1, 2023 | nasdaq.com

INBX Makes Bullish Cross Above Critical Moving Average

April 26, 2023 | msn.com

Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients

April 26, 2023 | finance.yahoo.com

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

April 13, 2023 | seekingalpha.com

Inhibrx: Undercovered Company With Good Potential

March 23, 2023 | finance.yahoo.com

The past year for Inhibrx (NASDAQ:INBX) investors has not been profitable

March 13, 2023 | benzinga.com

Inhibrx Stock (NASDAQ:INBX), Analyst Ratings, Price Targets, Predictions

March 7, 2023 | finanznachrichten.de

Inhibrx Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

March 6, 2023 | msn.com

Inhibrx GAAP EPS of -$0.95 misses by $0.16, revenue of $0.27M misses by $0.52M

See More Headlines

Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Company Calendar

Last Earnings: 8/07/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INBX
CUSIP: N/A
CIK: 1739614
Web: www.inhibrx.com
Phone: 858-795-4220
Fax: N/A
Employees: 132
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $44.33
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +141.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-145,230,000.00
Net Margins: -28,749.25%
Pretax Margin: -28,748.58%
Return on Equity: -5,168.31%
Return on Assets: -74.66%

Debt

Debt-to-Equity Ratio: 13.61
Current Ratio: 6.49
Quick Ratio: 6.49

Sales & Book Value

Annual Sales: $2.19 million
Price / Sales: 365.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 13.80

Miscellaneous

Outstanding Shares: 43,670,000
Free Float: 33,974,000
Market Cap: $801.34 million
Optionable: Not Optionable
Beta: 2.68

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Mark Paul Lappe (Age 56)
Founder, Chairman, Pres & CEO
Comp: $1.02M

Dr. Brendan P. Eckelman Ph.D. (Age 44)
Founder & Chief Scientific Officer
Comp: $704k

Ms. Kelly Devine Deck B.S. (Age 42)
CPA, M.S., Exec. VP & CFO
Comp: $531.17k

Mr. Quinn L. Deveraux
Founder

Dr. Ashraf Amanullah (Age 55)
Exec. VP & Chief Technical Operations Officer

Ms. Leah Pollema J.D.
VP, Corp. Sec. & Gen. Counsel

Dr. Charbel Helaihel Pharm.D.
VP of Marketing & Commercial Planning

Mr. Jeffrey J. Jensen
Exec. VP & Chief Clinical Operations Officer

Mr. David Matly M.B.A.
Exec. VP & Chief Commercial Officer

Dr. Carlos Bais Ph.D.
Exec. VP of Translational Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INBX Stock - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings or view top-rated stocks.
What is Inhibrx's stock price forecast for 2023?: 4 equities research analysts have issued 1 year price objectives for Inhibrx's stock. Their INBX share price forecasts range from $27.00 to $60.00. On average, they anticipate the company's stock price to reach $44.33 in the next twelve months. This suggests a possible upside of 141.6% from the stock's current price.
View analysts price targets for INBX or view top-rated stocks among Wall Street analysts.
How have INBX shares performed in 2023?: Inhibrx's stock was trading at $24.64 at the beginning of 2023. Since then, INBX stock has decreased by 25.5% and is now trading at $18.35.
View the best growth stocks for 2023 here.
Are investors shorting Inhibrx?: Inhibrx saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 4,810,000 shares, a decline of 5.5% from the August 31st total of 5,090,000 shares. Based on an average daily trading volume, of 426,700 shares, the short-interest ratio is presently 11.3 days. Approximately 14.4% of the shares of the stock are sold short.
View Inhibrx's Short Interest.
When is Inhibrx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our INBX earnings forecast.
How were Inhibrx's earnings last quarter?: Inhibrx, Inc. (NASDAQ:INBX) issued its quarterly earnings data on Monday, August, 7th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.06. The business had revenue of $0.03 million for the quarter. Inhibrx had a negative trailing twelve-month return on equity of 5,168.31% and a negative net margin of 28,749.25%.

What other stocks do shareholders of Inhibrx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).
When did Inhibrx IPO?: (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.
What is Inhibrx's stock symbol?: Inhibrx trades on the NASDAQ under the ticker symbol "INBX."
How do I buy shares of Inhibrx?: Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inhibrx's stock price today?: One share of INBX stock can currently be purchased for approximately $18.35.
How much money does Inhibrx make?: Inhibrx (NASDAQ:INBX) has a market capitalization of $801.34 million and generates $2.19 million in revenue each year. The company earns $-145,230,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.
How many employees does Inhibrx have?: The company employs 132 workers across the globe.
How can I contact Inhibrx?: Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.

This page (NASDAQ:INBX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial